Background: It remains controversial whether hormone therapy in recently postmenopausal women modifies the risk of Alzheimer's disease (AD). Objective: To investigate the effects of hormone therapy on amyloid-␤ deposition in recently postmenopausal women. Methods: Participants within 5-36 months past menopause in the Kronos Early Estrogen Prevention Study, a randomized, double blinded placebo-controlled clinical trial, were randomized to: 1) 0.45 mg/day oral conjugated equine estrogens (CEE); 2) 50 g/day transdermal 17␤-estradiol; or 3) placebo pills and patch for four years. Oral progesterone (200 mg/day) was given to active treatment groups for 12 days each month.
INTRODUCTION
Hormone therapy consisting of conjugated equine estrogens (CEE) along with medroxyprogesterone acetate initiated in the late postmenopause stage (≥ 65 years) increased the risk of dementia in the Women's Health Initiative Memory Study (WHIMS) [1] . However, there is controversy on whether estrogen with or without progesterone can preserve neurological function and decrease the risk of dementia when administered early in menopause, i.e., during a "window of opportunity" phase [2] [3] [4] [5] [6] [7] [8] .
Although determining the effects of hormone treatment shortly after menopause on the risk of dementia would require decades of follow-up, non-invasive imaging markers of Alzheimer's disease (AD) pathophysiology can potentially assess the efficacy of preventive interventions in the short term.
The Kronos Early Estrogen Prevention Study (KEEPS) was a multi-center, randomized, placebocontrolled, double-blinded trial of hormone treatment in recently menopausal women who were in good cardiovascular health. KEEPS tested the hypothesis that hormone therapies administered soon after the onset of menopause would slow progression of atherosclerosis; [9] however, no effect was observed on several imaging markers of progression of atherosclerosis during the four year trial [10] , or cognitive function [11] . Although estrogens, in particular, are thought to modify the risk of AD, estrogen effects on amyloid-␤ (A␤) pathology have not been investigated in a hormone treatment trial. Examining data obtained at one KEEPS enrollment site, we report the effects of two forms of hormone therapy, oral CEE and transdermal 17␤ estradiol therapy on A␤ deposition measured by Pittsburgh compound-B (PiB) PET.
METHODS

Participants
KEEPS (NCT00154180) was a multicenter, randomized, double blinded, placebo-controlled clinical trial in recently menopausal women (n = 727) that was conducted between 2006 and 2011. Participants enrolled in KEEPS were between 42 to 59 years of age, within 5 to 36 months past their last menses, and were in good cardiovascular health and did not have a history of hysterectomy or oophorectomy [9] . Estrogens were administered through two different routes: Oral or transdermal. Participants were randomized to either: 1) oral conjugated equine estrogen (CEE; Premarin, 0.45 mg/day); 2) transdermal 17␤-estradiol (skin patch, Climara, 50 g/day); or 3) placebo pills and patch. Progesterone was given orally (Prometrium; micronized progesterone, 200 mg/day) for the first 12 days each month to both active treatment groups. Participants were treated for four years.
Neuroimaging for the current study was conducted from December 2012 through July 2014 and included the subsample of women who were enrolled in KEEPS at the Mayo Clinic, to investigate the effects of the KEEPS hormone treatments on A␤ deposition three years after the end of the trial. This study was approved by the Mayo Clinic Institutional Review Board and all subjects or appropriate surrogates provided informed consent for participation Exclusion criteria for the imaging studies were contraindications for safety and neurologic disorders such as brain tumors, multiple sclerosis, neurodevelopmental abnormalities, or treatments (e.g., systemic chemotherapy) that would affect the brain structure. Apolipoprotein E (APOE) genotyping was performed after randomization and clinical examinations were performed at the Mayo Clinic Specialized Center of Research on Sex Differences within three months of the imaging studies. The study was approved by the Institutional Review Board at Mayo Clinic and all participants gave informed consent.
Neuropsychological assessment and cognitive function
A confirmatory factor analysis was used to assess the underlying structure of baseline cognitive data from the KEEPS cognitive and affective study (n = 662), and to derive summary scores [12] . Using standard criteria for model fit, the cognitive variables were summarized with a general domain representing global cognitive function at baseline.
A battery of neuropsychological tests three years after the end of the hormone therapy phase were administered within three weeks of the neuroimag- 
MRI and PET imaging
MRI studies were performed on a single 1.5T system, with an 8-channel phased-array coil (GE Healthcare). A 3D high resolution MPRAGE acquisition with TR/TE/TI = 7/3/900 ms; flip angle 8 degrees; in plane resolution of 1.0 mm and a slice thickness of 1.2 mm was performed for anatomical segmentation and labeling of PiB PET scans.
PET images were acquired using a PET/CT scanner (DRX; GE Healthcare) operating in 3D mode. The participants were injected with 292-729 MBq [ 11 C]PIB. A CT image was obtained for attenuation correction. After a 40-min uptake period, a 20-min PiB scan was obtained. The PiB-PET acquisition consisted of four 5-min dynamic frames, acquired from 40 to 60 min after injection. Standard corrections were applied. The pixel size for PET images was 1.0 mm and the slice thickness was 3.3 mm.
Analysis of PiB PET
PiB PET quantitative image analysis was performed using the fully automated image processing pipeline which has been described in detail elsewhere [13] . Briefly, the method includes gray matter (GM) sharpening of PET images using MRI and partial volume correction of cerebrospinal fluid and tissue compartments using Statistical Parametric Mapping unified segmentation algorithm [14] . PiB PET cortical ratio images were calculated by dividing each PiB PET GM voxel value by the median value in the cerebellar GM region in patient's MRI space. PiB retention was calculated by the PiB Standard unit value ratio (SUVR), with the median values of the PiB PET GM ratio from the bilateral parietal, posterior cingulate, precuneus, temporal, prefrontal, orbitofrontal, anterior cingulate GM regions in the in-house modified anatomical labeling atlas.
Statistical analysis
Characteristics of participants were compared across the treatment and the placebo groups using Kruskal-Wallis tests or Fisher exact tests, as appropriate. We also compared the characteristics of the participants and non-participants. Cognitive test scores were compared across the treatment and the placebo groups using ANOVA and Tukey's honest significant differences test for the post-hoc comparisons with adjustments. Age was tested for association with PiB SUVR using Spearman correlations. We performed the comparisons of PiB SUVR values across treatment and placebo groups, adjusting for age, using proportional odds logistic regressions [15] . This semiparametric model mitigates the effect of outliers while allowing for parametric effects of age and treatment, and simultaneously estimates the log (odds) of higher versus lower value of PiB SUVR, at all possible threshold values. Thus, we did not classify the participants into A␤-positive and A␤-negative categories based on PiB SUVR.
RESULTS
All women enrolled in KEEPS at the Mayo Clinic in Rochester, Minnesota (n = 118) were considered for participation in the current study. Six participants were excluded due to neurological disorders or MRI contraindications, forty women declined to participate in both MRI and/or PET studies, and four participants were lost to follow-up. Of the 112 eligible KEEPS participants, 68 women (61%) with median age of 60 (range, 52-65) participated in both the MRI and PET studies and were included in the analysis (Fig. 1 ). Participants included in the analysis did not differ from those who did not participate in the neuroimaging study on age (p = 0.09), education (p = 0.42), smoking status (p = 0.48), time past from menopause to randomization (p = 0.55), or APOE status (p = 0.47).
The time elapsed between last menses and randomization was on average ten months longer in the oral CEE (p = 0.05) and five months longer in the transdermal 17␤-estradiol group compared to placebo (p = 0.04). The transdermal 17␤-estradiol group had a higher proportion of APOE 4 carriers (50%) than the oral CEE (18%; p = 0.08) and the placebo groups (18%; p = 0.03). All APOE 4 carriers had the 4/3 genotype. Three women declined APOE genetic testing (Table 1 ). All participants were cognitively normal on clinical examination and neuropsychological testing. There were no correlations between neuropsychometric test scores and the PiB SUVR values in the entire group as well as in the oral CEE, transdermal 17␤-estradiol and placebo groups separately (p > 0.09). However, after adjusting for age, education, APOE 4 status, and time from menopause to randomization, CVLT Total Score was lower in the oral CEE group compared to placebo on ANOVA and post hoc Tukey's Honest Significant differences test (p = 0.03) ( Table 2) .
Because of a difference in the proportion of APOE 4 carriers among treatment groups, and the potential impact of this variable on outcome, a stratified analysis in APOE 4 carriers and non-carriers was conducted. There was a significant association of PiB SUVR with age in the whole group (r = 0.37; p = 0.002), in APOE 4 carriers (r = 0.48; p = 0.046), and in APOE 4 non-carriers (r = 0.43; p = 0.003). Therefore, all analyses were adjusted by age (Fig. 2) . The distribution of PiB SUVR varied by treatment group and by APOE 4 carrier status (Fig. 3) . Participants who were treated with 17␤-estradiol were were more likely to have lower PiB SUVR compared to placebo after adjusting for age [odds ratio (95%CI) = 0.31 (0.11-0.83)]. By use of the proportional odds model, this odds ratio applies to any possible cut-point for PiB SUVR. In the APOE 4 carriers (n = 18), transdermal 17␤-estradiol treated participants were more likely to have lower PiB SUVR compared to placebo [odds ratio (95%CI) = 0.04 (0.004-0.44)], and compared to the oral CEE treated participants [odds ratio (95%CI) = 0.01 (0.0006-0.23)] after adjusting for age. Treatment with either oral CEE or transdermal 17␤-estradiol was not associated with PiB SUVR in APOE 4 non-carriers (n = 47) (Fig. 4) .
DISCUSSION
This study of recently menopausal women who participated in a randomized controlled hormone therapy trial showed that A␤ deposition measured by PiB retention on PET was lower in women who received transdermal 17␤-estradiol for four years compared to placebo. In contrast, oral CEE was not associated with a lower level of PiB retention. Although the oral CEE group performed worse on verbal learning and memory compared to placebo, this finding should be interpreted with caution because of the small sample size and because no correlation was found between PiB retention and cognitive test scores. Stratified analysis by APOE 4 genotype showed that the lower PiB retention in the transdermal 17␤-estradiol group was present only in the APOE 4 carriers. Hormone therapy was not associated with PiB retention in APOE 4 non-carriers.
A precipitous decline in endogenous estrogens with menopause is thought to be a major driver of AD risk in women. Hence, hormone therapy with estrogens Fig. 2 . Associations of PiB SUVR with age in the whole group of participants, in APOE 4 carriers, and in APOE 4 non-carriers. Fig. 3 . PiB SUVR in the oral CEE, transdermal 17␤-estradiol, and the placebo groups in the whole group of participants, in APOE 4 carriers, and in APOE 4 non-carriers. Fig. 4 . Odds ratios for PiB SUVR from proportional odds logistic regression models and 95% Wald confidence limits comparing PiB SUVR in oral CEE, transdermal 17␤-estradiol, and the placebo groups in the whole group of participants, in APOE 4 carriers, and in APOE 4 non-carriers after adjusting for age. The odds ratio axis is logarithmic to accommodate the entire range of 95% Wald confidence limits.
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offers the possibility for preventing or delaying the onset of AD in aging women [6, 8, 16, 17] . Observational studies suggest that estrogen treatment, when administered to recently menopausal women, protects from age-associated cognitive decline and dementia [5, [17] [18] [19] [20] [21] [22] [23] [24] [25] . KEEPS was a randomized, placebocontrolled hormone therapy trial designed to test for intervention during the period of rapid estrogen depletion in recently menopausal women. Thus, KEEPS is ideally positioned to investigate the effects of hormone therapy on prevention of AD-related pathology during this "window of opportunity". PiB retention on PET imaging is a quantitative measure of A␤ deposition [26] . High A␤ deposition measured on PET imaging or via cerebrospinal fluid is considered to be the earliest biomarker change observed during the preclinical stages of AD [27, 28] . Thus, PiB retention on PET is an appropriate biomarker to investigate whether hormone therapy influences A␤ deposition specifically during the early menopausal years when the effect of A␤ deposition on cognitive function is not yet manifested. We observed no differences in cognitive function among the 17␤-estradiol and placebo groups. However, a randomized controlled trial of oral 17␤-estradiol in older women (age: 61-87) found less decline in short-delayed verbal recall compared to placebo [29] . Hence, the effects of lower levels of A␤ deposition in the transdermal 17␤-estradiol group on cognitive function may be apparent later in life.
Carriers of the APOE 4 allele are at an increased risk of AD dementia; moreover the risk may be higher in women than in men [30, 31] . APOE 4 carriers have increased A␤ deposition at an earlier age than APOE 4 non-carriers, and this difference is more pronounced in women than in men [32, 33] . Thus, women who are APOE 4 carriers are at a higher risk for AD-related pathology and may benefit most from preventive interventions at an early age. In the current study, we found that postmenopausal transdermal 17␤-estradiol is associated with lower levels of A␤ deposition compared to placebo particularly among women who are APOE 4 carriers. We interpret this finding in two possible ways.
The first possible interpretation is that APOE status modifies the effect of transdermal 17␤-estradiol on A␤ deposition as a pharmacogenetic effect. This interpretation is consistent with observations where APOE also modulates the effect of transdermal 17␤-estradiol therapy on A␤ deposition in live mice, [34] and in cultured adult mouse cortical neurons [35] . APOE 4 status appears to modify the effects of hormone therapy on cognitive function and dementia also in humans; however, the findings are conflicting [36] [37] [38] . In one observational study, APOE 4 positive women opting to use hormone therapy had lower risk of dementia, however, the forms of hormone therapy were not specified [36] . On the contrary, APOE 4 positive women had more cognitive decline than APOE 4 negative women if they used hormone therapy (primarily with oral CEE) in two other observational studies [37, 38] . Similarly, we did not find an association of oral CEE therapy with A␤ deposition compared to placebo. In fact, APOE 4 carriers treated with oral CEE showed higher levels of A␤ deposition than APOE 4 carriers treated with transdermal 17␤-estradiol. However because of the low number of APOE 4 carriers in the CEE group, this finding needs to be interpreted with caution. In WHIMS, oral CEE therapy along with medroxyprogesterone acetate, initiated in older women (age ≥ 65) increased the risk of dementia and brain atrophy, which persisted into older ages [1, 2, 39, 40] ; however, the APOE 4 status of women in WHIMS was not reported. Because CEE increases serum levels of estrone and of sulfonated conjugates more than transdermal 17␤-estradiol, it is possible that the various circulating estrogens would have different efficacy in binding and activation of estrogen receptor mediated events such as the deposition of A␤ [41] . Further work is needed to understand how higher doses of oral CEE (e.g., 0.625 mg/day as used in the Women's Health Initiative), may increase the circulating levels of 17␤-estradiol to those comparable to the transdermal 17␤-estradiol treatment group.
A second possible interpretation of the finding is that the APOE 4 non-carriers included in our study were too young to show hormone therapy effects on A␤ deposition. Participants recruited to the PET study three years after KEEPS were at a median age of 60 with a range of 52 to 65. In the population-based Mayo Clinic Study of Aging, the estimated age at which 10% of the population had high levels of A␤ deposition was 57 years for APOE 4 carriers and 64 years for APOE 4 non-carriers [42] . Thus, it may be too early to detect transdermal 17␤-estradiol effects on A␤ deposition in APOE 4 non-carriers in the current study. Further follow-up of the cohort is planned to determine whether transdermal 17␤-estradiol therapy in recently menopausal women is associated with A␤ deposition in older age.
This study was conducted at a single KEEPS site; therefore, the sample size is limited. Our findings need to be confirmed in a larger sample perhaps by including all KEEPS sites. The participation rate (with the exclusions) for this multimodality imaging study is comparable to the imaging participation rate observed in other hormone therapy trials such as the WHIMS-MRI study [40] . A higher proportion of APOE 4 carriers in the transdermal 17␤-estradiol group is not surprising given the relatively small number of women included this pilot study. Randomization does not guarantee a balanced allocation across treatment groups when the numbers are small. Lower A␤ deposition in the transdermal 17␤-estradiol group compared to placebo cannot be explained by the higher proportion of APOE 4 carriers in the transdermal 17␤-estradiol group than the placebo. In fact, the opposite would be expected, because A␤ deposition should be highest in a group with a higher proportion of APOE 4 carriers. Although the study cohort was randomized to hormone therapies and placebo 7 years ago, cardiovascular risk factors and biomarkers remained comparable in the oral CEE, transdermal 17␤-estradiol and placebo groups at 84 months (7 years) post-randomization. KEEPS was designed to include women who were in good cardiovascular and neurological health, therefore generalization of our findings to a broader population may be limited. Yet, in a homogenously healthy cohort of women, the potential effects of hormone therapy on A␤ deposition are not confounded by vascular disease and perhaps define a population who might benefit from the use of transdermal 17␤-estradiol.
The consequences of A␤ deposition during early menopausal years are not fully understood, and effectiveness of early menopausal hormone therapy in preventing AD-related pathology in the long-term remains unclear. However, reducing A␤ deposition through A␤-modifying therapies is a widely accepted strategy for preventing AD, and clinical trials are underway in cognitively normal individuals with high PiB retention, [43] and in APOE 4 carriers [44] . The association of transdermal 17␤-estradiol therapy in recently menopausal women with lower A␤ deposition has the potential to change the concepts for preventive interventions that drive the field, and may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.
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